Epizyme Inc. closed an underwritten public offering to raise gross proceeds of about $86.3 million.

The Cambridge, Mass.-based biopharmaceutical company offered 9,583,334 common shares at $9 each. The total number of shares includes 1,250,000 shares underwriters bought at the offering price after fully exercising their option.

Net proceeds will help fund global development and commercialization of cancer drug tazemetostat outside of Japan. Proceeds will also be used on clinical trials and regulatory activities for tazemetostat. Additionally, funds may go toward research and development costs for other potential products, as well as working capital and other general corporate purposes.

Jefferies acted as sole book-running manager for the offering.